Power to the Patients – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Power to the Patients

Brandon Li

Science

Frequency: 1 episode/19d. Total Eps: 42

Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com

Read moreCollapse

Site

RSS

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

No recent rankings available

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

No links shared by this podcast

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 53%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Why Clinical Trial Speed Kills Success - And What Top Sponsors Do Instead ft. Steve Brannan

Episode 14

Tuesday, October 21, 2025 • Duration 40:54

What if you could learn the secrets behind one of psychiatry's most significant breakthroughs in decades? In this episode of Power to the Patients, host Brandon Li sits down with Steve Brannan, Chief Medical Officer of Karuna Therapeutics, to explore the art of clinical trial excellence, the future of precision psychiatry, and the untold story behind developing the first new-mechanism schizophrenia drug in decades. Whether you're a researcher, clinician, or industry professional, this conversation reveals invaluable insights about trial methodology, site relationships, and the delicate balance between speed and quality in drug development. Tune in to discover why clinical operations excellence might be the most underappreciated factor in successful psychiatric drug development.

Read moreCollapse

Dr. Anantha Shekhar on the Convergence of Psychiatry, Neurology, and the Next Era of Brain Medicine

Episode 13

Wednesday, October 15, 2025 • Duration 50:05

In this episode of Power to the Patients, Brandon Li speaks with Dr. Anantha Shekhar, Senior Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of Pittsburgh. Dr. Shekhar shares how his early experiences with a family member’s schizophrenia inspired a lifelong mission to bridge neuroscience, psychiatry, and translational research. They explore how psychiatry and neurology are rapidly converging, why the future of mental health treatment lies in understanding brain circuits and plasticity, and what AI, precision medicine, and synthetic biology might mean for the next generation of therapies. Dr. Shekhar also reflects on his pioneering work developing xanomeline—the first novel mechanism of action for schizophrenia in over 70 years—and offers hard-won lessons on trial design, translational gaps, and maintaining scientific rigor in a complex field. A fascinating conversation on the science—and the humanity—behind reshaping how we understand and treat the brain.

Read moreCollapse

Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry

Episode 4

Friday, May 23, 2025 • Duration 47:26

Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience.

Read moreCollapse

Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass General Center on the Neuroscience of Psychedelics

Episode 3

Monday, May 12, 2025 • Duration 42:33

In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest in rumination—and its role in treatment-resistant mental illness—led them to explore psilocybin’s effects on brain connectivity. The conversation spans everything from neuroplasticity and default mode networks to the challenges of securing funding, the limits of industry-driven research, and what’s next in training the next generation of psychiatrists. It’s an honest, far-reaching discussion about where the science stands—and where it still needs to go.

Read moreCollapse

Spyros Papapetropoulos, CEO of Neuphoria

Episode 2

Monday, May 12, 2025 • Duration 42:17

Spyros Papapetropoulos, a leading neurologist and neuroscientist, joins Power CEO, Brandon Li, to discuss his remarkable career and the transformative work at Neuphoria. Spyros delves into his transition from practicing neurologist to drug development and his decision to focus on neuropsychiatric diseases. They explore Neuphoria's innovative approach to treating social anxiety disorder with their lead program, BNC210, which has shown promising results in reducing anxiety without the side effects of current treatments. Spyros and Brandon discuss unmet needs in psychiatric treatments, the operational challenges in clinical trials, and the evolving landscape of neuroscience - including the exciting advancements in imaging, biomarkers, and precision psychiatry.

Read moreCollapse

Steve Gourlay, CEO of Actinogen

Episode 1

Monday, April 28, 2025 • Duration 41:13

Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the strategic focus on Alzheimer's over depression due to unmet medical needs and the future direction in Alzheimer's research. Brandon and Steven also dive into the regulatory landscape, patient selection criteria, and the broader implications of Actinogen's work in transforming the treatment landscape for neurodegenerative diseases.

Read moreCollapse

Boehringer Ingelheim: Christine Sakdalan and Mike Jablonski talk precision psychiatry

Episode 16

Wednesday, April 9, 2025 • Duration 40:32

In this episode of Power to the Patients, Boehringer Ingelheim leaders Christine Sakdalan and Mike Jablonski from discuss how precision psychiatry—using tools like biomarkers and neuroimaging—can personalize treatment for conditions like schizophrenia and depression. They highlight the importance of holistic care, digital therapeutics, and industry collaboration to address unmet needs and improve outcomes in mental health.

Read moreCollapse

John Krystal: Advancing Ketamine Research & Psychiatry at Yale

Episode 15

Friday, March 7, 2025 • Duration 01:01:02

John Krystal, Chair of the Department of Psychiatry at Yale, joins Brandon Li to discuss his groundbreaking work on ketamine's antidepressant effects and the evolving landscape of psychiatric treatments. Dr. Krystal was at the forefront of the discovery of ketamine's rapid antidepressant properties in the 1990s. Dr. Krystal shares insights from his career - his pioneering work on the rapid antidepressant effects of ketamine, exploring its journey from a misunderstood drug to a revolutionary treatment backed by rigorous research, its development into a treatment by Johnson & Johnson, and its dramatic impact on patients. The conversation also explores the future of psychiatric research, addressing the convergence of neurobiology, psychotherapy, and neuromodulation to create more effective, personalized treatments for disorders like schizophrenia and depression.

Read moreCollapse

Next-Gen Treatments for Anxiety and Depression Disorders

Episode 14

Tuesday, February 25, 2025 • Duration 45:01

In this episode, Brandon sits down with Shawn Singh, CEO of Vistagen, to discuss a first-of-its-kind approach to treating mental health conditions. Vistagen is developing pherines, a new class of nasal spray treatments that work through nose-to-brain neural pathways, with the potential to provide fast-acting relief for conditions like social anxiety disorder and depression—without systemic exposure, weight gain, or addiction risk. Key Takeaways: Mental health treatments haven’t changed in decades. Traditional antidepressants come with slow onset, side effects, and compliance challenges—patients need better options. Vistagen’s pherines offer a completely new approach. These nasal sprays use neural circuits to deliver rapid effects without entering the bloodstream, eliminating common side effects. First-ever Phase 3 success for acute treatment of social anxiety disorder. Vistagen’s lead drug, Fasedienol, showed rapid and significant anxiety reduction in a public speaking challenge study. Non-systemic treatments could change the future of medicine. Unlike traditional pills, pherines don’t require processing through the liver or bloodstream—reducing toxicity and drug interactions. This could be a once-in-a-generation shift in neuroscience. If successful, pherines could reshape treatment standards for mental health and beyond.

Read moreCollapse

Precision Psychiatry and Emerging Technologies

Episode 13

Friday, February 21, 2025 • Duration 01:03:28

In this episode, Brandon Li sits down with Dr. Jordan Smoller - Jerrold F. Rosenbaum Chair in Psychiatry at Mass General, Co-Director for the Center for Suicide Research and Prevention at MGH and Harvard, Director of the Center for Precision Psychiatry, and a professor at Harvard Medical School, to explore the future of psychiatry. They discuss how AI, big data, and genomics are transforming mental health care—bringing us closer to precision psychiatry that moves beyond trial-and-error treatment. Dr. Smoller shares his journey from early psychiatric research to leading one of the foremost centers in precision psychiatry, tackling some of the biggest challenges in mental health. Key topics include: The promise of precision psychiatry – Why psychiatry has lagged behind other fields in precision medicine, and how AI and genomics are closing the gap. AI in suicide prevention – How electronic health records and machine learning models could predict suicide risk for earlier intervention. Rethinking antidepressant treatment – Why 50% of patients don’t respond to their first antidepressant, and how predictive modeling could reduce trial-and-error prescribing. Drug development breakthroughs – How genomics and AI are identifying new targets for psychiatric drug development and improving clinical trial success rates. Digital tools & biomarkers – The role of wearables, vocal biomarkers, and real-world data in improving diagnosis, treatment selection, and monitoring.

Read moreCollapse

Power to the Patients – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Power to the Patients – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities